Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Corline Biomedical AB's share price is €1.545.
Corline Biomedical AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.04. Hence, Corline Biomedical AB's PS Ratio for today is 41.76.
The historical rank and industry rank for Corline Biomedical AB's PS Ratio or its related term are showing as below:
FRA:IZ7'
s PS Ratio Range Over the Past 10 Years
Min: 7.54 Med: 54.22 Max: 405.17
Current: 44.52
During the past 13 years, Corline Biomedical AB's highest PS Ratio was 405.17. The lowest was 7.54. And the median was 54.22.
FRA:IZ7's PS Ratio is ranked worse than 77.31% of 930
companies
in the Biotechnology industry
Industry Median: 9.405
vs FRA:IZ7: 44.52
Corline Biomedical AB revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Corline Biomedical AB was 9.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -33.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 7.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 28.80% per year.
During the past 13 years, Corline Biomedical AB's highest 3-Year average Revenue per Share Growth Rate was 155.90% per year. The lowest was -34.70% per year. And the median was 1.85% per year.
Back to Basics: PS Ratio
Corline Biomedical AB (FRA:IZ7) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corline Biomedical AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corline Biomedical AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Corline Biomedical AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Corline Biomedical AB's Share Price of today is €1.545. Corline Biomedical AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Corline Biomedical AB (FRA:IZ7) has a PS Ratio of 41.76 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Corline Biomedical AB and its competitors. This is 23% below median its historical median of 54.22. Over the past decade, Corline Biomedical AB's PS Ratio has ranged from 7.54 to 405.17. According to the industry distribution chart, Corline Biomedical AB ranks #719 out of 930 companies in the Biotechnology industry, placing it in the top 77.3%.
Is Corline Biomedical AB's PS Ratio too high?
Corline Biomedical AB's current PS Ratio of 41.76 is 23% below median its 10-year median of 54.22. Over the past 10 years, this metric has ranged from a low of 7.54 to a high of 405.17. The Biotechnology industry median PS Ratio is 9.41. Corline Biomedical AB's value of 41.76 is 344% above this industry median. Based on the distribution chart, Corline Biomedical AB ranks #719 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corline Biomedical AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Corline Biomedical AB ranks #719 out of 930 companies for PS Ratio. This places Corline Biomedical AB in the lower half of its industry. The industry median PS Ratio is 9.41. Corline Biomedical AB's value of 41.76 is 344% above this benchmark. Historically, Corline Biomedical AB's own PS Ratio has ranged from 7.54 to 405.17 over the past decade. While the company's 10-year median is 54.22 vs. the industry median of 9.41, Corline Biomedical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.41, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corline Biomedical AB's current PS Ratio of 41.76 is 344% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Corline Biomedical AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corline Biomedical AB's current PS Ratio is 41.76, which is 23% below median its own 10-year median of 54.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Corline Biomedical AB (FRA:IZ7) has a current PS Ratio of 41.76. The stock's GF Value™ is €0.45, compared to a current price of €1.55 — trading 243.3% above its estimated fair value. The current PS Ratio is 41.76, which is 23% below median its 10-year median of 54.22 and 344% above the Biotechnology industry median of 9.41. Corline Biomedical AB's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Corline Biomedical AB (FRA:IZ7), the current PS Ratio is 41.76 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corline Biomedical AB (FRA:IZ7) Overvalued in 2026?
Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued.
The current stock price of €1.55 is trading 243.3% above its estimated GF Value™ of €0.45.
Key valuation signals for FRA:IZ7:
PS Ratio: 41.76 (23% below median its 10-year median of 54.22)
GF Value™: €0.45 vs. price of €1.55 (243.3% above fair value)
Industry Position: 344% above the Biotechnology median (#719 of 930)
No single metric tells the full story. See the FRA:IZ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score
Get the complete analysis for FRA:IZ7
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IZ7 has been successfully added to your 
